Skip to main content
. Author manuscript; available in PMC: 2020 Feb 1.
Published in final edited form as: Biomaterials. 2018 Dec 10;194:1–13. doi: 10.1016/j.biomaterials.2018.12.009

Figure 5: Viability of tissue-specific hiPSCs-derived cells cultured in the bioprinted dECM tissue constructs.

Figure 5:

(a) Representative Live/Dead™ images of the heart dECM and collagen I tissue constructs. Scale bar, 500 μm. (n=3). (b) CellTiter-Glo® 3D cell viability assay was used to measure the metabolic activity of the heart dECM tissue constructs relative to collagen I controls. All data are expressed as mean ± standard deviation, (n=3). (c) Representative images of heart dECM tissue constructs at 7 days with striated patterns and collagen I controls. Scale bar, 500 μm (5x) and 100 μm (10x). (d) Representative Live/Dead™ images of the liver dECM and collagen I tissue constructs. Scale bar, 500 μm. (n=3). (e) CellTiter-Glo® 3D cell viability assay showing measured metabolic activity of the liver dECM tissue constructs relative to collagen I controls. All data are expressed as mean ± standard deviation, (n=3). (f) Liver dECM tissue constructs at 7 days showing preservation of printed lobular patterns relative to collagen I controls. Yellow arrows point to vertices of the hexagonal pattern. Scale bar, 500 μm (5x) and 100 μm (10x).

HHS Vulnerability Disclosure